1. Patients with pre-existing lung disorders (including pulmonary fibrosis, COPD, severe asthma, lung cancer, etc).2. Patients with confirmed severe or life-limiting chronic disease, or a history of angioedema prior to COVID-19 infection.3. Pregnancy or lactation period.4. Subjects of childbearing age who are not using an adequate method of contraception prior to their inclusion in the study.5. Subject that they are receiving another product under investigation.6. Known hypersensitivity to any of the components of the formulation under study.7. Obvious mental incapacity to issue consent and act accordingly with the study.

1. Patients with pre-existing lung disorders (including pulmonary fibrosis, COPD, severe asthma, lung cancer, etc).2. Patients with confirmed severe or life-limiting chronic disease, or a history of angioedema prior to COVID-19 infection.3. Pregnancy or lactation period.4. Subjects of childbearing age who are not using an adequate method of contraception prior to their inclusion in the study.5. Subject that they are receiving another product under investigation.6. Known hypersensitivity to any of the components of the formulation under study.7. Obvious mental incapacity to issue consent and act accordingly with the study.

1. Pregnancy, postpartum and breastfeeding.2. Subjects of childbearing age who are not using an adequate method of contraception prior to their inclusion in the study (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms).3. Known hypersensitivity to any component of the CIMAvax-EGF formulation.4. Patient receiving other investigational product.5. Obvious mental incapacity to give consent and act accordingly with the study.

1. Pregnancy, postpartum and breastfeeding.2. Subjects of childbearing age who are not using an adequate method of contraception prior to their inclusion in the study (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms).3. Known hypersensitivity to any component of the CIMAvax-EGF formulation.4. Patient receiving other investigational product.5. Obvious mental incapacity to give consent and act accordingly with the study.